The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment
Published version of a preprint
Abstract
A hallmark of pancreatic ductal adenocarcinoma (PDAC) is an exuberant stroma comprised of diverse cell types that enable or suppress tumor progression. Here, we explored the role of oncogenic KRAS in protumorigenic signaling interactions between cancer cells and host cells. We show that KRAS mutation (KRAS*) drives cell-autonomous expression of type I cytokine receptor complexes (IL2rγ–IL4rα and IL2rγ–IL13rα1) in cancer cells that in turn are capable of receiving cytokine growth signals (IL4 or IL13) provided by invading Th2 cells in the microenvironment. Early neoplastic lesions show close proximity of cancer cells harboring KRAS* and Th2 cells producing IL4 and IL13. Activated IL2rγ–IL4rα and IL2rγ–IL13rα1 receptors signal primarily via JAK1–STAT6. Integrated transcriptomic, chromatin occupancy, and metabolomic studies identified MYC as a direct target of activated STAT6 and that MYC drives glycolysis. Thus, paracrine signaling in the tumor microenvironment plays a key role in the KRAS*-driven metabolic reprogramming of PDAC. Significance: Type II cytokines, secreted by Th2 cells in the tumor microenvironment, can stimulate cancer cell–intrinsic MYC transcriptional upregulation to drive glycolysis. This KRAS*-driven heterotypic signaling circuit in the early and advanced tumor microenvironment enables cooperative protumorigenic interactions, providing candidate therapeutic targets in the KRAS* pathway for this intractable disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a KRASG12D mutation driven PDAC mice model, immune suppressive cytokines IL-4 and IL-13 and remodeling of the myeloid cell composition in TME have been demonstrated40,41.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [41]
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Trapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204 · cited 3×
“Five microliters of cells (5 × 105) mixed with 5 μL Matrigel was injected.”
MethodInfluentialDang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390 · cited 1×
“IL4 and IL13 Upregulate MYC to Promote Metabolic Reprogramming Oncogenic MYC is known to cooperate with KRAS* in driving many cancers and contributes to many cancer hallmarks (21, 22), including cancer cell survival (23, 24), cancer initiation and progression (24, 25), and metabolic reprogramming of bioenergetic pathw…”
BackgroundOncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationGlutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
Self-citationChronic inflammation and cytokines in the tumor microenvironment
Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014) · Journal of Immunology Research · doi:10.1155/2014/149185 · Cited by 1,765
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1252 · Cited by 1,660
Genetics and biology of pancreatic ductal adenocarcinomaPreprint
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. M., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,611
Self-citationAmir, E.-A. D., Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H., Bendall, S. C., Shenfeld, D. K., Krishnaswamy, S., Nolan, G. P., & Pe'er, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2594 · Cited by 1,550 · cited 1×
“Data were analyzed with FlowJo (Tree Star) and viSNE (61).”
Method
Cited by
Sorted by citations
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 811
Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer
Alam, A., Levanduski, E., Denz, P. J., Villavicencio, H. S., Bhatta, M., Alhorebi, L., Zhang, Y., Gomez, E. C., Morreale, B. G., Senchanthisai, S., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.003 · Cited by 372
Self-citationCell death in pancreatic cancer: from pathogenesis to therapy
Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 344
Metabolic Codependencies in the Tumor Microenvironment
Dey, P., Kimmelman, A. C., & DePinho, R. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1211 · Cited by 349
Self-citationSTAT proteins in cancer: orchestration of metabolism
Li, Y., Zhang, C., Martincuks, A., Herrmann, A., & Yu, H. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-022-00537-3 · Cited by 305
Metadata
- Authors
- Dey, P., Li, J., Zhang, J., Chaurasiya, S., Strom, A., Wang, H., Liao, W.-T., Cavallaro, F., Denz, P., Bernard, V., Yen, E.-Y., Genovese, G., Gulhati, P., Liu, J., Chakravarti, D., Deng, P., Zhang, T., Carbone, F., Chang, Q., Ying, H., Shang, X., Spring, D. J., Ghosh, B., Putluri, N., Maitra, A., Wang, Y. A., & DePinho, R. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of Houston (US)
- 3Center for Nuclear Receptor and Cell Signaling, University of Houston, Houston, Texas.
- 1Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Roswell Park Comprehensive Cancer Center (US)
- Baylor College of Medicine (US)
- Corresponding author
- DePinho, Ronald A.
- ORCID
- Dey, Prasenjit
- Li, Jun
- Zhang, Jianhua
- Chaurasiya, Surendra
- Wang, Huamin
- Liao, Wen-Ting
- Cavallaro, Frederick
- Denz, Parker
- Bernard, Vincent
- Yen, Er-Yen
- Genovese, Giannicola
- Gulhati, Pat
- Liu, Jielin
- Chakravarti, Deepavali
- Deng, Pingna
- Zhang, Tingxin
- Carbone, Federica
- Chang, Qing
- Ying, Haoqiang
- Shang, Xiaoying
- Spring, Denise J.
- Putluri, Nagireddy
- Maitra, Anirban
- Wang, Y. Alan
- DePinho, Ronald A.
- Venue
- Cancer Discovery
- Published
- 2020-04-01
- Volume
- 10
- Issue
- 4
- Pages
- 608-625
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3006227213
- Cited by
- 213
- References
- 65
- Citations by year
- 2026: 30 · 2025: 33 · 2024: 33 · 2023: 33 · 2022: 40 · 2021: 36 · 2020: 8
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- MD Anderson (P30CA16672)
- Baylor College of Medicine (P30CA125123)
- CPRIT (RP170005, RP140106170067, 170067)
- NCI (P01 CA117969, R01 CA225955)
- DOD (W81XWH-14-1-0429, K99/R00, 1K99 CA218891-01A1, U24 CA224020, R01 CA218004, R01 CA304969)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- pancreatic ductal adenocarcinoma, oncogenic KRAS, tumor microenvironment, metabolic reprogramming, glycolysis, c-Myc, STAT6, IL-4, IL-13, Th2 cells, paracrine signaling, tumor stroma
- MeSH terms
- Animals, Humans, Oncogenes, Pancreatic Neoplasms, Transfection, Cytokines, Proto-Oncogene Proteins p21(ras), Mice, Tumor Microenvironment, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
